Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amarin Corp ADR
(NQ:
AMRN
)
0.6148
+0.0286 (+4.88%)
Streaming Delayed Price
Updated: 2:24 PM EST, Nov 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amarin Corp ADR
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Amarin Corp: Q2 Earnings Insights
August 03, 2022
Amarin Corp (NASDAQ:AMRN) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session
July 01, 2022
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 56.1% to $ 0.7029 after dropping 10% on Thursday.
Via
Benzinga
Sarissa Capital Intends to Vote “Abstain” at the Amarin Annual Meeting
June 15, 2022
From
Sarissa Capital Management LP
Via
Business Wire
Amarin Outlines $100M Cost Saving Plan
June 06, 2022
Via
Benzinga
Recap: Amarin Corp Q1 Earnings
May 04, 2022
Amarin Corp (NASDAQ:AMRN) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For March 1, 2022
March 01, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...
Via
Benzinga
Akerna Shares Dip 53%, Here's 78 Biggest Movers From Yesterday
July 01, 2022
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase...
Via
Benzinga
Looking Into Amarin Corp's Return On Capital Employed
May 16, 2022
Amarin Corp (NASDAQ:AMRN) brought in sales totaling $94.63 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 314.74%, resulting in a loss of $31.56 million.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2022
May 06, 2022
Upgrades For Coupang Inc (NYSE:CPNG), JP Morgan upgraded the previous rating of Neutral to Overweight. The stock has a 52-week-high of $46.00 and a 52-week-low of $11.91. At the end of the last trading...
Via
Benzinga
A Peek Into The Markets: US Stock Futures Down; Jobs Report In Focus
May 06, 2022
Pre-open movers
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2022
May 05, 2022
Upgrades
Via
Benzinga
10 Biggest Price Target Changes For Thursday
May 05, 2022
Needham cut Cirrus Logic, Inc. (NASDAQ: CRUS) price target from $110 to $100. Cirrus Logic shares rose 4.5% to close at $82.81 on Wednesday.
Via
Benzinga
81 Biggest Movers From Yesterday
May 05, 2022
Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares climbed 62.4% to close at $2.16 on Wednesday after gaining around 5% on Tuesday.
Via
Benzinga
Mid-Afternoon Market Update: Crude Oil Jumps 5%; Fed Boosts Interest Rates By 0.5%
May 04, 2022
U.S. stocks traded mixed toward the end of trading, after the Federal Reserve announced its policy decision.
Via
Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
May 04, 2022
Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares jumped 51.7% to $2.0180 after gaining around 5% on Tuesday. Sharps Technology, Inc. (NASDAQ: STSS) rose 31.4% to $1.6815 after...
Via
Benzinga
Mid-Day Market Update: Dow Rises 100 Points; Lyft Shares Plummet
May 04, 2022
U.S. stocks traded mixed midway through trading, with the Dow Jones gaining more than 100 points on Wednesday.
Via
Benzinga
Mid-Morning Market Update: Markets Mixed; Nasdaq Tumbles 100 Points
May 04, 2022
U.S. stocks traded mixed this morning, with the Nasdaq dropping more than 100 points on Wednesday.
Via
Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
May 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
May 04, 2022
Via
Benzinga
Amarin Corp's Earnings: A Preview
May 03, 2022
Amarin Corp (NASDAQ:AMRN) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Amarin Corp...
Via
Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
May 02, 2022
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...
Via
Benzinga
NASDAQ:AMRN Long Term Investor Notice: Investigation of Potential Wrongdoing at Amarin Corporation Plc
March 09, 2022
San Diego, CA -- (SBWIRE) -- 03/09/2022 -- An investigation was announced for investors in shares of Amarin Corporation plc (NASDAQ:AMRN) concerning potential breaches of fiduciary duties by certain...
Via
SBWire
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
March 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...
Via
Benzinga
Lower Vascepa Volume Hits Amarin's Q4 Topline Growth
March 01, 2022
Amarin Corp plc's (NASDAQ: AMRN) Q4 FY21 sales decreased 13.6% Y/Y to $144.49 million, beating the consensus of $141.75 million. The decline was driven primarily by...
Via
Benzinga
Amarin: Q4 Earnings Insights
March 01, 2022
Amarin Corp (NASDAQ:AMRN) reported its Q4 earnings results on Tuesday, March 1, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...
Via
Benzinga
28 Stocks Moving In Tuesday's Mid-Day Session
January 25, 2022
Gainers Sierra Oncology, Inc. (NASDAQ: SRRA) shares jumped 47.8% to $22.93 after the company unveiled topline data for momelotinib in myelofibrosis patients who are symptomatic,...
Via
Benzinga
51 Biggest Movers From Yesterday
January 26, 2022
Gainers Sierra Oncology, Inc. (NASDAQ: SRRA) shares climbed 46.2% to close at $22.68 on Tuesday after the company unveiled topline data for momelotinib in myelofibrosis patients...
Via
Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data
January 25, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Pfizer, BioNTech Initiates Study Of Omicron-Based Vaccine Candidate Pfizer,...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
January 25, 2022
Good morning, investor! We're starting off the day right with a dive into the biggest pre-market stock movers for Tuesday!
Via
InvestorPlace
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.